TY - JOUR
T1 - CEACAM6 gene expression in intrahepatic cholangiocarcinoma
AU - Ieta, K.
AU - Tanaka, F.
AU - Utsunomiya, T.
AU - Kuwano, H.
AU - Mori, M.
N1 - Funding Information:
We thank T Shimooka, K Ogata, M Oda, M Kasagi, and Y Nakagawa for their technical assistance. This work was supported in part by the following grants and foundations: a Grant-in-Aid for Scientific Research on Priority Areas of Cancer (14026037, 15023245) and Grants-in-Aid for development of far advanced medicine (B) (2002–2005), from the Ministry of Education, Culture, Sports, Science and Technology of Japan, a Grant-in-Aid for Scientific Research (S) (17109013), (B) (14370358, 15390398, 15390379, 16390381) and (C) (14570149, 14571140, 15591412, 15591411), YASUDA Medical Research Foundation, Sankyo Foundation of Life Science, and a Grant-in-Aid for Exploratory Research (14657286, 16659337, 1665960) from the Japan Society for Promotion of Science.
PY - 2006/8/21
Y1 - 2006/8/21
N2 - The purpose of this study was to investigate the clinicopathological and biological significance of human carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) gene expression in human intrahepatic cholangiocarcinoma. CEACAM6 is reported to be involved in human malignancies. However, in cholangiocarcinoma expression of CEACAM6 and its clinicopathological significance have not been investigated. CEACAM6 expression status was determined and analysed with respect to various clinicopathological parameters in 23 intrahepatic cholangiocarcinomas. Additionally, we investigated effects of CEACAM6 gene in the cholangiocarcinoma cell lines. CEACAM6 gene expression in cancer tissues was higher than in noncancerous tissues in 16 of the 23 cases; however, it was not statistically significant. The tumours with elevated CEACAM6 expression showed a tendency to be associated with lymphatic invasion and stage of the disease. Interestingly, patients with high CEACAM6 expression showed a significantly poorer disease-free survival rate than those with low CEACAM6 expression. We demonstrated that CEACAM6-transfected cells were more proliferative, more invasive and more chemoresistant to gemcitabine compared to mock-transfected cells. Furthermore, CEACAM6 gene silencing by CEACAM6-specific siRNA resulted in higher chemosensitivity to gemcitabine. CEACAM6 is a potential prognostic indicator and potential chemoresistant marker to gemcitabine for patients with intrahepatic cholangiocarcinoma.
AB - The purpose of this study was to investigate the clinicopathological and biological significance of human carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) gene expression in human intrahepatic cholangiocarcinoma. CEACAM6 is reported to be involved in human malignancies. However, in cholangiocarcinoma expression of CEACAM6 and its clinicopathological significance have not been investigated. CEACAM6 expression status was determined and analysed with respect to various clinicopathological parameters in 23 intrahepatic cholangiocarcinomas. Additionally, we investigated effects of CEACAM6 gene in the cholangiocarcinoma cell lines. CEACAM6 gene expression in cancer tissues was higher than in noncancerous tissues in 16 of the 23 cases; however, it was not statistically significant. The tumours with elevated CEACAM6 expression showed a tendency to be associated with lymphatic invasion and stage of the disease. Interestingly, patients with high CEACAM6 expression showed a significantly poorer disease-free survival rate than those with low CEACAM6 expression. We demonstrated that CEACAM6-transfected cells were more proliferative, more invasive and more chemoresistant to gemcitabine compared to mock-transfected cells. Furthermore, CEACAM6 gene silencing by CEACAM6-specific siRNA resulted in higher chemosensitivity to gemcitabine. CEACAM6 is a potential prognostic indicator and potential chemoresistant marker to gemcitabine for patients with intrahepatic cholangiocarcinoma.
UR - http://www.scopus.com/inward/record.url?scp=33747171944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33747171944&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6603276
DO - 10.1038/sj.bjc.6603276
M3 - Article
C2 - 16868542
AN - SCOPUS:33747171944
SN - 0007-0920
VL - 95
SP - 532
EP - 540
JO - British journal of cancer
JF - British journal of cancer
IS - 4
ER -